RENALYTIX PLC LS-0025 (F:2O9) — Market Cap & Net Worth
Market Cap & Net Worth: RENALYTIX PLC LS-0025 (2O9)
RENALYTIX PLC LS-0025 (F:2O9) has a market capitalization of $18.57 Million (€15.89 Million) as of September 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #25455 globally and #2177 in its home market, demonstrating a 39.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RENALYTIX PLC LS-0025's stock price €0.07 by its total outstanding shares 437018680 (437.02 Million).
RENALYTIX PLC LS-0025 Market Cap History: 2020 to 2026
RENALYTIX PLC LS-0025's market capitalization history from 2020 to 2026. Data shows change from $2.68 Billion to $34.49 Million (-51.92% CAGR).
RENALYTIX PLC LS-0025 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RENALYTIX PLC LS-0025's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check RENALYTIX PLC LS-0025 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2O9 by Market Capitalization
Companies near RENALYTIX PLC LS-0025 in the global market cap rankings as of September 17, 2026.
Key companies related to RENALYTIX PLC LS-0025 by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #738 globally with a market cap of $37.44 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #1902 globally with a market cap of $12.23 Billion USD ( AU$17.28 Billion AUD).
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2076 globally with a market cap of $11.06 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2133 globally with a market cap of $10.63 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #738 | Veeva Systems Inc Class A | NYSE:VEEV | $37.44 Billion | $266.62 |
| #1902 | Pro Medicus Ltd | AU:PME | $12.23 Billion | AU$165.45 |
| #2076 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $11.06 Billion | $68.85 |
| #2133 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $10.63 Billion | $58.84 |
RENALYTIX PLC LS-0025 Historical Marketcap From 2020 to 2026
Between 2020 and today, RENALYTIX PLC LS-0025's market cap moved from $2.68 Billion to $ 34.49 Million, with a yearly change of -51.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €34.49 Million | +8.00% |
| 2025 | €31.93 Million | -44.69% |
| 2024 | €57.73 Million | -39.57% |
| 2023 | €95.54 Million | -73.29% |
| 2022 | €357.64 Million | -90.07% |
| 2021 | €3.60 Billion | +34.29% |
| 2020 | €2.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of RENALYTIX PLC LS-0025 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.57 Million USD |
| MoneyControl | $18.57 Million USD |
| MarketWatch | $18.57 Million USD |
| marketcap.company | $18.57 Million USD |
| Reuters | $18.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About RENALYTIX PLC LS-0025
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more